Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Ongoing | Cancer Accelerated Approvals
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
VYJUVEK
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-09-15 By FDA
Human medicines European public assessment report (EPAR): Baqsimi, glucagon, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
Generic Drug User Fee Amendments
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
GDUFA Paid Facilities List
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
FDA Online Controlled Substances Summit, Washington, D.C. - 09/11/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
Human medicines European public assessment report (EPAR): Emselex, darifenacin hydrobromide, Date of authorisation: 22/10/2004, Revision: 28, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 22, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
Human medicines European public assessment report (EPAR): Thalidomide Lipomed, thalidomide, Date of authorisation: 19/09/2022, Revision: 2, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
Human medicines European public assessment report (EPAR): Locametz, gozetotide, Date of authorisation: 09/12/2022, Revision: 7, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-09-15
Advancing Generic Drug Development: Translating Science to Approval 2025 - 10/07/2025
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-15 By FDA
Influenza (Flu) Antiviral Drugs and Related Information
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
From Our Perspective
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA
CDER Pilot Grant Program: Standard Core Clinical Outcome Assessments (COAs) and their Related Endpoints
Source: FDA - What's New: Drugs RSS Feed Published on 2025-09-12 By FDA

Предыдущие записи

Тема: Scaffold от Danny Cooper.